Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Instinctif Partners

16:25 EST 9th December 2018 | BioPortfolio

Here are the most relevant search results for "Instinctif Partners" found in our extensive news archives from over 250 global news sources.

More Information about Instinctif Partners on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Instinctif Partners for you to read. Along with our medical data and news we also list Instinctif Partners Clinical Trials, which are updated daily. BioPortfolio also has a large database of Instinctif Partners Companies for you to search.

Showing News Articles 1–25 of 760 from Instinctif Partners

Thursday 6th December 2018

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and convenient oral antibiotic for gonorrhoea treatment SYDNEY, AUSTRALIA– 6 December 2018 -. SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae (GC) and sequences in the...

Monday 3rd December 2018

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

CAMBRIDGE, UK – 3 December 2018 – Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect. Dr Edmunds has over 15 years’ pharmaceutic...

Thursday 29th November 2018

Final Results for year ended 31 May 2018: Invoiced sales up 51% following significant contract, investment and restructuring

Cambridge, UK, 29 November 2018 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its full year results for the year to 31 May 2018. Operational highlights (including post period end) CE marked release of TexRAD® Lung in November 2017 Restructuring in April 2018 brought TexRAD Ltd and Cambridge...

Monday 26th November 2018

Immune Regulation announces positive results from Phase 1 clinical trial of PIN201104.

Confirmed clean safety profile No serious or severe adverse effects Primary endpoints of safety and pharmacokinetic data achieved Stevenage, UK, 26 November 2018 - Immune Regulation Ltd. (‘Immune Regulation’ or the ‘Company’, formerly known as Peptinnovate), a biopharmaceutical company developing “first in class” immune-resetting therapies for as...

Thursday 22nd November 2018

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Stevenage, UK, 22 November, 2018 - Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com. Rich...

Tuesday 20th November 2018

Commencement of final phase of human studies

Manchester, UK – 20 November 2018 – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, announces the commencement of the third and final phases of its human study and provides a summary of key scientific and commercial milestones achieved so far in 2018. Commencement of final pha...

Wednesday 7th November 2018

SkinBiotix® technology generates positive data in first two elements of its human study

Manchester, UK – 7 November 2018 – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces positive data from the first two elements of its human study which focus on skin irritancy and moisturisation potential. As previously announced on 19 September 2018, the third, main element of the human study will commenc...

Monday 5th November 2018

Xellia Pharmaceuticals Announces the Launch of First US Market Product Vancomycin Hydrochloride for Injection, USP.

Now offering Vancomycin HCl, USP 10 g and 1 g lyophilized powder in the United States market Buffalo Grove, IL, and Copenhagen, Denmark - 5 November 2018 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has launched Vancomycin Hydrochloride for Injection, USP within the United States market. &ldqu...

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

Cambridge, UK, 5 November 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement. Takeda has taken an exclusive licence to Humabodies directed to one of its oncology target...

Friday 2nd November 2018

Breakthrough in Rapid Diagnostic for Antimicrobial Resistance

DNAe achieves major milestone in a novel clinical sequencing platform, successfully completing the first phase of its $51.9 million contract with US government’s BARDA London, UK and Carlsbad, CA, USA – 2 November 2018 – A rapid new diagnostic platform that harnesses the power of semiconductor DNA sequencing, promises to revolutionise the ability of physicians to treat antimi...

Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards

Cambridge, UK, 2 November 2018 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel. Microbiotica was recognised for a year of continued development in the fast-growing microbiome space. ...

Dr. Axel Mescheder Appointed CEO of Cristal Therapeutics as Focus Intensifies on Proprietary Oncology Nanomedicine Pipeline

Maastricht, The Netherlands - 2 November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). Dr. Mescheder joi...

Tuesday 30th October 2018

Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®

Cambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November. Mike Romanos, CEO of Microbiotica, will participate in the Microbiome and the Implication on Other Therapeutic Areas along with panellists from Entero...

Friday 26th October 2018

Recce Meets Antibiotic Leaders to Explore Commercial and Clinical Opportunities

Sydney, Australia – 26 October 2018 – Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it will be represented at the World Anti-Microbial Resistance Congress in Washington D.C., 25 - 26 October 2018. The conference features 150 speakers from 20 countries and is a leading international forum for researchers, investors...

Thursday 25th October 2018

SkinBioTherapeutics plc - Full year results

Manchester, UK – 25 October 2018 - SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”) a life sciences company focused on skin health, has announced its full year audited results for the year to 30 June 2018. Key highlights SkinBiotix® passed key cytotoxicity safety test Replication of lysate manufacturing proc...

Proposed placing and subscription to raise £1.375 million

Cambridge, 25 October 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that it has conditionally raised a total of £1.375 million (before expenses) via a proposed placing, by Peterhouse Capital Limited, and subscription of a total of 91,666,666 new ordinary shares (“New Ordinary Shares”...

Wednesday 24th October 2018

Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund

Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how Joins founding investors, Cambridge Innovation Capital and IP Group, by committing £4m, bringing total equity raised to £12m Cambridge, UK, 24 October 2018 – Mic...

Tuesday 23rd October 2018

Epilepsy Society, UCL and Congenica Join Forces in Genomic Study to Identify Causes of Unexpected Deaths in Epilepsy

Sudden unexpected death in epilepsy (SUDEP) occurs in approximately 1/1000 people with epilepsy and is poorly understood Genomic studies will seek to identify underlying genetic causes, to improve clinical understanding Cambridge, United Kingdom – 23 October, 2018 – Congenica, the global diagnostic decision support platform provider, today announced a key partnership wit...

Monday 22nd October 2018

Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure

Groningen, The Netherlands, 22 October 2018 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage f...

Feedback expands its European customer base with new orders for TexRAD® from prestigious European university hospitals

Cambridge, 22 October 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company, Feedback Medical Ltd, has received a number of substantial orders for TexRAD®, its patented image texture analysis technology, from prestigious university hospitals across Europe. The orders have come...

Thursday 18th October 2018

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Cambridge, UK, 18 October 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer. Richard will manage Crescendo’s internal CMC act...

Tuesday 16th October 2018

DNAe Wins OBN Award for Best Diagnostic Medtech Company

London, UK and Carlsbad, CA, USA – 16 October 2018 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, was named ‘Best Diagnostic Medtech Company’ at the 2018 OBN Awards. Marking its 10th anniversary, the prestigious OBN Awards recognize and cel...

Monday 15th October 2018

F-star Appoints Dr Eliot Forster as Chief Executive Officer.

Cambridge, UK – 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum. Eliot brings more than 25 years of extensive leadership experience ...

Thursday 11th October 2018

Doubts Over Data Security Denting Smart Inhaler Potential?

Cambridge, UK – 11 October 2018 – As many as 800 asthma deaths a year in the UK could be prevented by a new generation of ‘smart inhalers’, however, data concerns could be holding back roll out, says medical device developer and manufacturer, Bespak. Michael Earl, Commercial Director at Bespak commented, “Data shows that nearly all patients don’t always use ...

Tuesday 9th October 2018

New PBS-Only Antibodies Enable More Flexible Research

Cambridge, UK – 9 October 2018 – Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments. Typically, antibodies are stored in a buffer composed of bovine serum albumin (BSA), glycerol and sodium azide to ensure stability. However...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks